S 3751119th CongressIn Committee
Prescription Drug Supply Chain Pricing Transparency Act
Standard Summary
Balanced plain-English summary
This bill requires the Comptroller General to study and report on price-related compensation and payment structures throughout the retail prescription drug supply chain. The study would examine intermediaries such as pharmacy benefit managers, Part D plan sponsors, wholesalers, pharmacies, manufacturers, pharmacy services administrative organizations, brokers, auditors, consultants, and rebate aggregators, including business models, affiliated versus unaffiliated entities, conflicts of interest, trends, and factors driving these arrangements. A report to Congress with recommendations would be due within two years.
Key Points
- 1Requires a GAO study of price-related compensation and payment structures in the prescription drug supply chain.
- 2Covers intermediaries including PBMs, Part D sponsors, wholesalers, pharmacies, manufacturers, PSAOs, brokers, and rebate aggregators.
- 3Examines business models, affiliated versus unaffiliated entities, conflicts of interest, and pricing trends.
- 4Requires a report to Congress within two years with legislative and administrative recommendations.
Impact Areas
Medicare Part D beneficiariesPatientsPharmacy benefit managersPharmaciesDrug manufacturersWholesalersPart D plan sponsorsFederal policymakers
Generated by deepseek/deepseek-v4.1-flash-1017Nov 18, 2026